Resveratrol supplementation reduces ACE2 expression in human adipose tissue.
Marlies de LigtMatthijs K C HesselinkJohanna JorgensenNicole HoebersEllen E BlaakGijs H GoossensPublished in: Adipocyte (2021)
Angiotensin converting enzyme-2 (ACE2) is the cell-surface receptor enabling cellular entry of SARS-CoV-2. ACE2 is highly expressed in adipose tissue (AT), rendering AT a potential SARS-CoV-2 reservoir contributing to massive viral spread in COVID-19 patients with obesity. Although rodent and cell studies suggest that the polyphenol resveratrol alters ACE2, human studies are lacking. Here, we investigated the effects of 30-days resveratrol supplementation on RAS components in AT and skeletal muscle in men with obesity in a placebo-controlled cross-over study. Resveratrol markedly decreased ACE2 (~40%) and leptin (~30%), but did neither alter angiotensinogen, ACE and AT1R expression in AT nor skeletal muscle RAS components. These findings demonstrate that resveratrol supplementation reduces ACE2 in AT, which might dampen SARS-CoV-2 spread in COVID-19.
Keyphrases
- angiotensin converting enzyme
- sars cov
- angiotensin ii
- insulin resistance
- adipose tissue
- skeletal muscle
- respiratory syndrome coronavirus
- endothelial cells
- metabolic syndrome
- poor prognosis
- type diabetes
- coronavirus disease
- cell surface
- weight loss
- randomized controlled trial
- weight gain
- single cell
- high fat diet induced
- stem cells
- binding protein
- long non coding rna
- atomic force microscopy
- clinical trial
- case control
- study protocol
- climate change
- high resolution
- risk assessment
- wild type
- bone marrow
- phase ii
- open label
- rectal cancer